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ABSTRACT
Objective Desmoplasia and hypovascularity are
thought to impede drug delivery in pancreatic ductal
adenocarcinoma (PDAC). However, stromal depletion
approaches have failed to show clinical responses in
patients. Here, we aimed to revisit the role of the
tumour microenvironment as a physical barrier for
gemcitabine delivery.
Design Gemcitabine metabolites were analysed in LSL-
KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) murine
tumours and matched liver metastases, primary tumour
cell lines, cancer-associated ﬁbroblasts (CAFs) and
pancreatic stellate cells (PSCs) by liquid chromatography-
mass spectrometry/mass spectrometry. Functional and
preclinical experiments, as well as expression analysis of
stromal markers and gemcitabine metabolism pathways
were performed in murine and human specimen to
investigate the preclinical implications and the
mechanism of gemcitabine accumulation.
Results Gemcitabine accumulation was signiﬁcantly
enhanced in ﬁbroblast-rich tumours compared with liver
metastases and normal liver. In vitro, signiﬁcantly
increased concentrations of activated 20,20-
diﬂuorodeoxycytidine-50-triphosphate (dFdCTP) and
greatly reduced amounts of the inactive gemcitabine
metabolite 20,20-diﬂuorodeoxyuridine were detected in
PSCs and CAFs. Mechanistically, key metabolic enzymes
involved in gemcitabine inactivation such as hydrolytic
cytosolic 50-nucleotidases (Nt5c1A, Nt5c3) were
expressed at low levels in CAFs in vitro and in vivo, and
recombinant expression of Nt5c1A resulted in decreased
intracellular dFdCTP concentrations in vitro. Moreover,
gemcitabine treatment in KPC mice reduced the number
of liver metastases by >50%.
Conclusions Our ﬁndings suggest that ﬁbroblast drug
scavenging may contribute to the clinical failure of
gemcitabine in desmoplastic PDAC. Metabolic targeting
of CAFs may thus be a promising strategy to enhance
the antiproliferative effects of gemcitabine.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is con-
sidered one of the most aggressive solid tumours
with increasing incidence worldwide.1 By 2030,
PDAC is projected to become the second leading
cause of cancer-related deaths following lung
cancer in the USA.2 Over several decades, gemcita-
bine has remained the standard of care
Signiﬁcance of this study
What is already known on this subject?
▸ Pancreatic ductal adenocarcinoma (PDAC) and
liver metastases are characterised by
pronounced tumour stroma consisting of
activated cancer-associated ﬁbroblasts (CAFs),
and abundant extracellular matrix
components.
▸ Depletion of stromal components by
various pharmacological approaches has
resulted in increased intratumoural
gemcitabine levels suggesting that the tumour
stroma may act as physical barrier for drug
delivery.
▸ Depletion of CAFs has been shown to promote
tumour growth and spread.
What are the new ﬁndings?
▸ Primary human and murine pancreatic tumours
show an increased number of α-smooth muscle
actin-positive ﬁbroblasts compared with
matched liver metastases. Murine primary
tumours accumulate signiﬁcantly more
gemcitabine metabolites.
▸ In CAFs and pancreatic stellate cells (PSCs),
signiﬁcantly higher intracellular concentrations
of gemcitabine metabolites were identiﬁed, in
comparison to tumour cell lines derived from
primary murine PDAC and metastases.
▸ Lower expression of key inactivating enzymes,
such as hydrolytic cytosolic 50-nucleotidases in
CAFs and PSCs increase the intracellular
concentration of gemcitabine when compared
with cancer cells and may serve as targets for
stromal reprogramming.
How might it impact on clinical practice in
the foreseeable future?
▸ CAFs and PSCs entrap active gemcitabine
intracellularly and may thus limit the
availability of the drug for cancer cells.
▸ Targeting the metabolic machinery of
ﬁbroblasts may enhance local availability of
gemcitabine in the tumour without interfering
with the tumour-restraining properties of
CAFs.
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chemotherapy despite only marginal effects on patient survival.3
More recently, FOLFIRINOX (oxaliplatin, irinotecan, leucov-
orin and 5-ﬂuorouracil (5-FU)) and nab-paclitaxel+gemcitabine
have extended the panel of available chemotherapies, for the
ﬁrst time achieving signiﬁcant survival beneﬁts for patients with
metastatic PDAC.4 5 However, increased rates of toxicity often
limit the frequent clinical use of both regimens in patients with
PDAC. More than any other solid cancer, PDAC is characterised
by abundant tumour stroma with activated cancer-associated
ﬁbroblasts (CAFs) that maintain a dense biophysical meshwork
around neoplastic ductal cells consisting of components such as
hyaluronic acid, ﬁbronectin, secreted protein acidic and rich in
cysteine (SPARC) and collagens.6 Besides the complex biochem-
ical cancer-stroma crosstalk,7–9 the distinct stromal architecture
has been postulated to create physical barriers for drug delivery,10
and sparked a new era of stromal depletion approaches.11
Indeed, subsequent preclinical investigations introduced alter-
native strategies to successfully deplete stromal ﬁbrosis and
relieve vessel compression. For instance, degradation of hya-
luronan and collagen, as well as reduced ﬁbrosis following
vitamin-D receptor activation in pancreatic stellate cells (PSCs)
resulted in increased drug delivery and response to gemcitabine
treatment in various genetically engineered mouse models
(GEMMs).12–15 Furthermore, some studies reported stromal
ablation on nab-paclitaxel administration in mice and humans
suggesting intratumoural nab-paclitaxel sequestration via
binding of stromal SPARC to albumin-coated paclitaxel.16 17
However, others have not observed stromal depletion on nab-
paclitaxel,18–20 and a recent evaluation of 256 patients from a
large phase III clinical trial did not show a correlation of
stromal SPARC expression and overall survival on nab-paclitaxel
+gemcitabine treatment.21 Consequently, the concept of the
stroma acting as physical barrier to prevent gemcitabine and
other therapeutic molecules to enter the tumour has been chal-
lenged recently. Studies in patients with PDAC using CT-derived
transport properties showed signiﬁcant interpatient and intratu-
moural heterogeneity of gemcitabine incorporation into the
DNA despite similar intravascular pharmacokinetics. Notably,
stromal content correlated with gemcitabine incorporation only
after accounting for levels of human equilibrative nucleoside
transporter 1 (hENT1).22 23 Further preclinical and clinical data
have conﬁrmed the observation that levels of the gemcitabine
transporter hENT1, the activating enzyme deoxycytidine kinase
(dCK) and the inactivating enzyme cytidine deaminase (Cda)
correspond with survival in patients and preclinical response to
gemcitabine,18 24–26 suggesting that gemcitabine metabolism
rather than biophysical properties matter most. Moreover, lim-
itations of past experimental studies assessing drug delivery in
murine pancreatic tumours included the use of different analyt-
ical methods such as nuclear MRI (19F NMR) and liquid
chromatography-mass spectrometry/mass spectrometry (LC-MS/
MS). Both methods cannot be compared directly as 19F NMR is
unable to distinguish all gemcitabine metabolites, and is less sen-
sitive.27 Vascular function and drug delivery studies with doxo-
rubicin and ﬂuorophore-labelled lectin could only assess very
early time-points after drug administration (∼5 min), thus cap-
turing a snapshot of intratumoural drug accumulation that may
not be representative of the genuine pharmacokinetic and phar-
macodynamic properties of gemcitabine. Thus, the relevance of
vessel patency and mean vessel density (MVD) for gemcitabine
delivery may have been overestimated using these short-time
assays. Notably, PDAC tissue analysis was limited to the tumour
bulk, and consequently distinction between tumour and stromal
cells was not possible.
In order to overcome these limitations, we recently analysed
the pharmacokinetic and pharmacodynamic proﬁle of gem-
citabine in LSLKrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC)
tumours over time using LC-MS/MS as the most sensitive
detection method for gemcitabine metabolites. Whereas
serum concentrations of the gemcitabine prodrug
20,20-diﬂuorodeoxycytidine (dFdC) peaked 1 hour after intraper-
itoneal injection, intratumoural accumulation of the activated
gemcitabine metabolite 20,20-diﬂuorodeoxycytidine-50-triphos-
phate (dFdCTP) reached maximum levels only after 2 hours and
coincided with the maximum induction of apoptotic cell death
as evidenced by cleaved caspase-3 immunohistochemistry.28
Using this standardised protocol, we here revisit the pharma-
cokinetic proﬁle of gemcitabine in murine PDAC in vitro and
vivo, and dissect the stromal and the neoplastic compartment of
primary tumours and matched liver metastases. Our ﬁndings
offer an alternative explanation for the clinical failure of gemci-
tabine in stroma-rich PDAC.
MATERIALS AND METHODS
For details, see online supplementary material and methods.
Human pancreatic cancer specimen
PDAC tumour samples with matched liver metastases were
obtained from formalin-ﬁxed and parafﬁn-embedded (FFPE)
tissue blocks collected for clinical purposes at Karolinska
Institute. The PDAC diagnosis was conﬁrmed by a staff path-
ologist at Karolinska Institute. Ethical approval was obtained
from Karolinska Institutional Review Board (EPN D-No.
2014/2147-31/1). Tissue microarrays with PDAC (n=50) were
assembled from representative FFPE archival tissue blocks that
had been sampled from pancreatoduodenectomy specimens at
Oslo University Hospital, Norway. Each tumour was repre-
sented by two 1.0 mm cores. Permission for the study was
obtained from the Regional Committee for Medical and
Health Research Ethics for Southern Norway (REK nr.
S-05081).
Preclinical mouse studies
For pharmacokinetic studies, gemcitabine was administered at
100 mg/kg by intraperitoneal injections. Tissues were harvested
2 hours after gemcitabine administration.
Liquid chromatography-mass spectrometry/mass
spectrometry
Gemcitabine (dFdC, 20,20-diﬂuorodeoxyuridine, dFdCTP) and 5-FU
Fresh frozen tumour samples were processed and analysed using
LC-MS/MS as previously described.27 Brieﬂy, LC-MS/MS for
gemcitabine and metabolites was performed on a TSQ Vantage
triple stage quadrupole mass spectrometer (Thermo Fisher
Scientiﬁc, USA) ﬁtted with a heated electrospray ionisation II
probe operated in positive and negative mode at a spray voltage
of 2.5 kV, capillary temperature of 150°C. Quantitative data
acquisition was done using LC Quan2.5.6 (Thermo Fisher
Scientiﬁc). LC-MS/MS for 5-FU was performed by the CRUK
Cambridge Institute Pharmacokinetics & Bioanalytics (PKB)
Core Facility, as previously described,29 but using a Sciex 6500
Triple Quad mass spectrometer with electrospray ionisation at
500°C.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism
V.6.05 (GraphPad Software). The Mann-Whitney non-
parametric U test was used unless indicated otherwise, and
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results are presented as mean±SE; p<0.05 was considered to
be statistically signiﬁcant.
RESULTS
Gemcitabine accumulation is increased in KPC tumours
compared with liver metastases and normal liver tissue but
does not correlate with survival
To determine whether overall survival in KPC mice is associated
with intratumoural concentrations of gemcitabine, in particular
the active, cytotoxic metabolite, we re-analysed n=10 KPC bulk
tumours from a previously published preclinical trial28 for
dFdCTP 2 hours after the last gemcitabine dose. Interestingly,
there was no correlation of intratumoural dFdCTP amount and
survival of KPC mice (Pearson’s r=0.23) suggesting that active
gemcitabine in bulk tumour tissue might not be a suitable
predictor of response to treatment (see online supplementary
ﬁgure S1A). For the combined primary tumour and liver metas-
tasis study, we dosed tumour-bearing KPC mice with 100 mg/kg
gemcitabine intraperitoneally. At this point, all mice had large
pancreatic tumours with metastatic disease corresponding to stage
IV pancreatic cancer in patients (ﬁgure 1A,B). As determined
earlier,28 peak tumour concentrations of gemcitabine are reached
2 hours after intraperitoneal injection. Therefore, all mice (n=15)
were sacriﬁced exactly 2 hours after gemcitabine administration,
and fresh frozen samples from liver metastases, primary tumours
and healthy liver tissue were immediately harvested. Using
LC-MS/MS, we analysed the concentration of gemcitabine dFdC,
the inactive metabolite 20,20-diﬂuorodeoxyuridine (dFdU) and the
active, cytotoxic gemcitabine metabolite dFdCTP using a previ-
ously established protocol.27 Surprisingly, the mean gemcitabine
concentration was signiﬁcantly higher in primary pancreatic
tumours compared with liver metastases (8.1 ng/mg, 95% CI 4.4
to 11.8 vs 4.6 ng/mg, 95% CI 2.0 to 7.2; p<0.05) (ﬁgure 1C).
The inactive metabolite dFdU did not signiﬁcantly differ among
the groups (ﬁgure 1D). Mean dFdCTP concentrations were not
signiﬁcantly elevated in primary tumours compared with liver
metastases (4.5 ng/mg, 95% CI 1.3 to 7.7 vs 2.3 ng/mg 95% CI
0.8 to 3.8; not signiﬁcant), but mean dFdCTP concentration was
highly signiﬁcantly elevated in primary tumours compared with
corresponding normal liver specimen (4.5 ng/mg, 95% CI 1.3 to
7.7 vs 0.59 ng/mg, 95% CI 0.15 to 1.0; p<0.002) (ﬁgure 1E).
Primary murine and human pancreatic tumours feature
higher stromal content than matched liver metastases
We reasoned that either stromal composition or vascularisation
of the different tumour tissues may account for the signiﬁ-
cantly different gemcitabine concentrations. To this end,
we systematically assessed and compared the desmoplastic reac-
tion of primary KPC tumours and matched liver metastases
(n=8) by biochemical and immunohistochemical methods.
Immunohistochemistry for α-smooth muscle actin (α-SMA),
collagen and SPARC provided clear evidence that desmoplasia,
in particular ﬁbroblast density, was reduced in liver metastases
compared with matched primary tumours (ﬁgure 2A–C).
Western blot analysis of KPC tumours (n=5) and matched liver
metastases (n=5) further corroborated these ﬁndings showing
low expression of important stromal components such as ﬁbro-
nectin, SPARC and α-SMA in metastases (ﬁgure 2D). Healthy
control liver tissue did not show immunoreactivity against such
stromal components, whereas the epithelial marker E-cadherin
was robustly expressed (ﬁgure 2D). As expected, normal liver
tissue revealed very low amounts of activated ﬁbroblasts and
Figure 1 Pharmacokinetic proﬁle of gemcitabine metabolites in primary pancreatic tumours, liver metastases and normal liver tissue in
corresponding KPC mice. (A) Necropsy view of a KPC mouse with a large pancreatic tumour (dotted blue circle) and several liver metastases (white
arrows). (B) H&E staining of a representative KPC tumour with matched liver metastasis. NL, normal liver, LM, liver metastasis. Scale bars, 50 mm.
(C) Tumour-bearing KPC mice were treated with one dose of gemcitabine at 100 mg/kg intraperitoneally. Tumour tissues, liver metastases and
normal liver tissue were excised and assessed for gemcitabine metabolites 2 hours later by liquid chromatography-mass spectrometry/mass
spectrometry (n=15). Gemcitabine is signiﬁcantly elevated in primary tumours compared with liver metastases (p<0.05) and normal liver tissue
(p<0.02). (D) The deaminated and inactive metabolite 20,20-diﬂuorodeoxyuridine (dFdU) shows no signiﬁcant differences among the three groups.
(E) The triple phosphorylated active gemcitabine metabolite 20,20-diﬂuorodeoxycytidine-50-triphosphate (dFdCTP) is signiﬁcantly increased in primary
pancreatic tumours as compared with normal liver tissue (p<0.01).
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extracellular matrix components (ﬁgure 2A). MVD was ana-
lysed by CD31 immunohistochemistry and did not signiﬁcantly
differ between primary tumours (n=8) and liver metastases
(n=8) (ﬁgure 2E).
To validate our ﬁndings in human specimen, we analysed a
small cohort of patients with pancreatic cancer (n=11) with
matched primary tumours and liver metastases. Although both
tissues showed a clear desmoplastic reaction with heterogeneous
Figure 2 Primary tumours display higher stromal content than liver metastases. (A) Representative pictures of collagen, secreted protein acidic and
rich in cysteine (SPARC) and α-smooth muscle actin (α-SMA) stains from primary murine pancreatic tumours and matched liver metastases (LM)
with adjacent normal liver (NL) reveal increased cellular and acellular desmoplasia in primary tumours. Scale bars, 50 mm. (B and C) Automated
quantiﬁcation of n=8 primary tumours and n=8 liver metastases reveal signiﬁcant increase in collagen and α-SMA area in primary tumours
(p<0.01; Wilcoxon matched-pairs signed-rank test). (D) Western blot analysis of whole tissue lysates from KPC primary tumours (n=5), liver
metastases (n=5) and normal liver tissue (n=1) conﬁrm higher α-SMA, SPARC and ﬁbronectin levels compared with liver metastases and normal
liver. HSP90, heat shock protein 90. (E) Immunohistochemical CD31 analysis reveals comparable mean vessel density (MVD) in primary tumours
(n=8) and liver metastases (n=8), whereas normal liver tissue (n=8) featured signiﬁcantly higher MVD (p<0.01; Wilcoxon matched-pairs signed-rank
test). Scale bars, 25 mm. PDAC, pancreatic ductal adenocarcinoma.
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distribution throughout the lesions, α-SMA-positive area was
markedly reduced in all liver metastases compared with
matched primary tumours (ﬁgure 3A, B).
Since the highest concentrations of gemcitabine were detected
in primary pancreatic tumours, our results suggested that the
stromal microenvironment may promote, rather than impede
gemcitabine accumulation in bulk tissue.
CAFs and PSCs show signiﬁcantly elevated levels
of intracellular gemcitabine in vitro
Due to the observation that MVD did not correlate with intratu-
moural gemcitabine uptake, we hypothesised that the cellular
components of the tumour would determine drug accumulation.
Therefore, we generated primary cell lines from pancreatic
tumours (n=4) and metastatic foci (n=4) from four different
KPC mice. To dissect the stromal and neoplastic compartment,
we further generated primary CAF lines (n=2) from murine
pancreatic tumours as well as PSCs (n=3) from healthy B6 mice
showing typical spindle-shaped morphology, and strong expres-
sion of α-SMA, SPARC and ﬁbronectin (ﬁgure 4A and online
supplementary ﬁgure S1B). The veriﬁcation of CAFs was deter-
mined by PCR for the excised lox-stop-lox site of KrasG12D (see
online supplementary ﬁgure S1C). Following standardised treat-
ment with 1 mM gemcitabine for 2 hours, cell pellets and super-
natants were subjected to LC-MS/MS analysis. We found no
signiﬁcant differences in dFdCTP concentrations between CAFs
(n=2) and PSCs (n=2) (see online supplementary ﬁgure S2A),
and also no signiﬁcant differences between tumour cell lines
derived from primary tumours or metastatic lesions (ﬁgure 4B).
However, we detected threefold to ﬁvefold higher concentration
of dFdCTP in ﬁbroblasts (PSCs and CAFs) compared with
neoplastic cells (p<0.03) (ﬁgure 4B). Gemcitabine and dFdU
were below the level of quantiﬁcation in all cells after 2 hours
of treatment. In cell culture media, LC-MS/MS analysis revealed
an approximately ﬁvefold lower concentration of inactive dFdU
from ﬁbroblasts compared with supernatant from neoplastic
cells (2.6 ng/mL, 95% CI 1.9 to 3.2 vs 12 ng/mL, 95% CI 5.7
to 18.4 for primary tumour cells, and 13.4 ng/mL, 95% CI 5.8
to 21.0 for metastatic tumour cells; p<0.03) (ﬁgure 4C).
Notably, gemcitabine concentrations remained above 570 nM
(150 ng/mL) in the media of all cell lines, and therefore were
unlikely to be the limiting factor (ﬁgure 4D). To investigate
whether this observation was speciﬁc for gemcitabine, we per-
formed LC-MS/MS analysis for 5-FU in the same cell lines.
Interestingly, we found no difference in 5-FU concentrations in
the cell culture supernatant between the different cell types, and
detected lower intracellular amounts of 5-FU in ﬁbroblasts com-
pared with various tumour cell lines (see online supplementary
ﬁgure S2B, C). These data suggest that the intracellular concen-
tration of dFdCTP is signiﬁcantly higher in ﬁbroblasts (CAFs
and PSCs), when compared with neoplastic cells from primary
tumours or metastatic lesions, and this effect was not observed
for 5-FU suggesting drug metabolism rather than drug uptake as
potential mechanism of action. As dFdCTP cannot cross the cell
membrane, it is entrapped intracellularly in ﬁbroblasts and is
thus not available for tumour cells. And indeed, conditioned
media of two CAF cell lines that were pretreated with gemcita-
bine for 24 hours at therapeutically relevant concentrations
(GI50 of tumour cells) signiﬁcantly increased tumour cell viabil-
ity by 40%–80% in two KPC cell lines compared with
CAF-conditioned media with fresh gemcitabine, suggesting a
gemcitabine scavenging effect of CAFs in vitro (ﬁgure 4E, F).
Figure 3 Human primary tumours reveal higher α-smooth muscle actin (α-SMA) content compared with matched liver metastases. (A) α-SMA
immunohistochemistry of human primary pancreatic ductal adenocarcinoma (PDAC) with matched liver metastases of n=11 patients. Scale bars,
50 mm. (B) The α-SMA score was signiﬁcantly higher in primary tumours compared with matched liver metastases (p<0.004; Wilcoxon
matched-pairs signed-rank test).
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Gemcitabine inactivating genes are expressed at low levels
in stromal cells in vitro and in vivo
Gemcitabine activation and inactivation is a complex multistep
process that is driven by a number of enzymes and cellular
transporters (see online supplementary ﬁgure S3). Reduced
levels of dFdU in the supernatant of ﬁbroblasts compared with
tumour cells pointed towards the possibility that little gemcita-
bine inactivation may occur in these cells. Rapid metabolic
inactivation of gemcitabine is predominantly catalysed by Cda
or deoxycytidylate deaminase (Dctd).30 To investigate the mech-
anism of increased levels of dFdCTP in ﬁbroblasts, we deter-
mined mRNA expression of a comprehensive panel of 15 genes
involved in gemcitabine transport and metabolism (Ent1, Ent2,
Cnt1, Cnt2, Nt5c1A, Nt5c3, Dctd, Rrm1, Rrm2, Rrm2b, Rpe,
Rpia, TK2, dCK and Cda) in primary cell lines from pancreatic
tumours, liver metastases and ﬁbroblasts (PSCs and CAFs).
Among these, only four genes were signiﬁcantly downregulated
in ﬁbroblasts compared with cancer cells (Nt5c1A, Nt5c3,
Rrm2 and Ent2) (ﬁgure 5A–C and online supplementary ﬁgure
S4). Apart from low expression of Ent2 and Rrm2 that would
not sufﬁciently explain high gemcitabine levels in ﬁbroblasts,31
Nt5cA genes are a class of hydrolytic cytosolic 50-nucleotidases
that catalyse the hydrolysis of dFdCMP to gemcitabine. Low
expression of Nt5c1A in ﬁbroblasts may thus contribute to an
increased pool of dFdCMP in ﬁbroblasts that ultimately culmin-
ate in higher dFdCTP concentrations.32 To experimentally
address this hypothesis, we stably transfected two murine PSC
lines with Nt5c1A and treated with gemcitabine for 2 hours.
Strikingly, LC-MS/MS analysis showed signiﬁcantly reduced
dFdCTP levels on Nt5c1A overexpression in both cell lines
(ﬁgure 5D and online supplementary ﬁgure S5).
For in vivo studies, KPC mice were screened by high-resolution
ultrasound prior to enrolment for appropriate tumour onset (6–
9 mm diameter). Gemcitabine was administered at 100 mg/kg
intraperitoneally every 3–4 days until end point. To assess gemci-
tabine metabolising proteins in murine and human PDAC, we
performed immunohistochemistry of gemcitabine-treated KPC
mice (n=24, median survival 12 days) and patient samples
(n=50, median survival 15 months). Nt5c1A was strongly
expressed in all murine and human tumour cells, whereas the
tumour microenvironment was largely devoid of Nt5c1A
expression (ﬁgure 5E). Cda and Dctd were not differentially
expressed in ﬁbroblasts and tumour cells at the mRNA level in
vitro (see online supplementary ﬁgure S4), however, immunohis-
tochemistry clearly demonstrated that Cda and Dctd were
expressed at very low levels in stromal cells and robustly
expressed in neoplastic cells in human and murine PDAC (ﬁgure
5E and online supplementary ﬁgure S6A, B). Notably, the main
gemcitabine activating enzyme dCK was expressed in the stromal
and neoplastic compartment of murine (n=24) and human
PDAC (n=50) (ﬁgure 5E and online supplementary ﬁgure S6C,
D). However, survival of mice and humans could not be corre-
lated to stromal Cda, Nt5c1A and Dctd levels as the expression
was very low in the stromal compartment in almost all cases. For
Figure 4 Fibroblasts accumulate activated gemcitabine while inactivation is decreased. (A) Typical morphology and α-smooth muscle actin
immunoreactivity of cancer associated ﬁbroblasts (CAFs) using immunocytochemistry. (B) Murine CAFs (n=2) and pancreatic stellate cells (PSCs)
(n=2) as well as primary cell lines from KPC pancreatic tumours (n=4) and metastatic foci (n=4) were cultured and treated with 1 mM gemcitabine
for 2 hours. Cell pellets and cell supernatants were subjected to liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) for
analysis. 20,20-Diﬂuorodeoxycytidine-50-triphosphate (dFdCTP) was signiﬁcantly increased in cell pellets from ﬁbroblasts (PSCs and CAFs), compared
with tumour cells (p<0.03). (C) The inactivated 20,20-diﬂuorodeoxyuridine (dFdU) was signiﬁcantly decreased in ﬁbroblasts compared with tumour
cells (p<0.03) indicating a greatly reduced gemcitabine inactivation in those cells. (D) Equal amounts of native gemcitabine
(20,20-diﬂuorodeoxycytidine (dFdC)) was detectable 2 hours after administration in cell culture supernatant. (E and F) 72 hours MTT assay with
conditioned media (CM) of CAF1 and CAF2 preincubated for 24 hours with 30 nM gemcitabine in KPC1 (GI50 32 nM) and KPC2 (GI50 25 nM) cells
shows signiﬁcant increase in cell viability compared with CAF1 and CAF2 control media with fresh 30 nM gemcitabine prior to 72 hours treatment
(KPC1—CAF1: p<0.002; KPC1—CAF2: p<0.04 and KPC2—CAF1: p<0.01, KPC2—CAF2: p<0.03; two-tailed, unpaired t-test).
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dCK, high stromal expression did not correlate with signiﬁcantly
shortened survival in humans (14 months for high stromal dCK
vs 16 months for low stromal dCK) and mice (15 days for high
stromal dCK vs 11 days for low stromal dCK).
Gemcitabine reduces metastatic burden in KPC mice
Taken together, these results suggest that low expression of
several gemcitabine inactivating enzymes in ﬁbroblasts results in
increased concentrations of gemcitabine within the stromal
compartment. To further characterise the cellular components
of the tumour bulk, we analysed the number of α-SMA-positive
ﬁbroblasts and pan-cytokeratin-positive tumour cells in n=25
untreated KPC mice and found around three times more
tumour cells (mean number 122/high power ﬁelds (HPF)) com-
pared with ﬁbroblasts (mean number 44/HPF, p<0.0001) (see
online supplementary ﬁgure S7A, B). As human pancreatic
tumours feature even more desmoplasia compared with
GEMMs, and endothelial cells are often directly surrounded by
Figure 5 Gemcitabine inactivating genes are expressed at low levels in stromal cells in vitro and in vivo. RNA isolated from murine cancer
associated ﬁbroblasts (CAFs) (n=2) and pancreatic stellate cells (PSCs) (n=2) as well as primary cell lines from KPC pancreatic tumours (n=4) and
metastatic foci (n=4) were subjected to quantitative reverse transcription-PCR. Gemcitabine metabolising enzymes were signiﬁcantly downregulated
in ﬁbroblasts compared with tumour cells for (A) 50-nucleotidase, cytosolic IA (Nt5c1A, p<0.03 and <0.03, respectively), (B) 50-nucleotidase,
cytosolic III (Nt5c3, p<0.03). (C) Deoxycytidine kinase (dCK) was not signiﬁcantly different in ﬁbroblasts compared with tumour cells (p=0.4); ns,
not signiﬁcant. (D) Gemcitabine treatment with 1 mM for 2 hours in PSC1 and PSC2 stably overexpressing Nt5c1A shows signiﬁcant reduction of
20,20-diﬂuorodeoxycytidine-50-triphosphate (dFdCTP) (p<0.01 and <0.001, respectively, two-tailed, unpaired t-test). (E) Representative
immunohistochemical pictures of murine and human tumour tissue showing cytidine deaminase (Cda), deoxycytidylate deaminase (Dctd) and
Nt5c1A expression in tumour cells, whereas stromal cells (arrows) are almost completely devoid of immunoreactivity. dCK is robustly expressed in
stromal cells (quantiﬁcation see online supplementary ﬁgure S6). Scale bars, 50 mm.
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Figure 6 Gemcitabine treatment does not induce apoptosis in ﬁbroblasts in vivo but reduces metastatic burden in KPC mice. (A and B) Archived
tissue from primary pancreatic KPC tumours was evaluated retrospectively. Gemcitabine treatment had been administered every 3–4 days for 9 days.
The last dose was given 2 hours prior sacriﬁce. Co-immunoﬂuorescence (Ki67, red; α-smooth muscle actin (α-SMA), green) shows no signiﬁcant
difference in proliferation rate in α-SMA-positive cells after 9 days gemcitabine treatment (two-tailed, unpaired t-test), Scale bar, 50 mm. (C and D)
Co-immunochemistry for α-SMA and CC3 does not show signiﬁcant differences on gemcitabine treatment in KPC mice (two-tailed, unpaired t-test;
arrow indicates apoptotic ﬁbroblast). Scale bar, 50 mm. (E and F) Total number of all liver metastases and small liver metastases in 10 serial liver
sections in a historical cohort of KPC mice treated with gemcitabine (n=8) or vehicle (n=8) for 9 days shows reduction of liver metastases by >50%.
(G) Representative H&E of a small liver metastasis from KPC mouse (dotted circle) and normal liver tissue (NL). (H) Ultrasound volume
measurements of corresponding mice reveals marginal response (−14%) on gemcitabine treatment for 9 days.
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ﬁbroblasts and not tumour cells,10 it seems plausible that a signiﬁ-
cant number of gemcitabine metabolites may be trapped intra-
cellularly in CAFs and thus are not available for tumour cells.
Given the fact that stromal cells showed signiﬁcantly higher con-
centrations of active gemcitabine compared with tumour cells
(ﬁgure 4B), we asked whether the differential gemcitabine
metabolism in tumour cells and ﬁbroblasts results in increased
gemcitabine sensitivity of ﬁbroblasts in vitro and in vivo. CAFs
are freely proliferative in vitro, and 72 hours 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue (MTT)
assays showed comparable GI50 for gemcitabine (20–30 nM) in
primary murine tumour cell lines (KPC n=2), tumour cells
derived from metastatic foci (KPCm n=2) and ﬁbroblasts (CAF
n=2) (see online supplementary ﬁgure S8A, B). In vivo, we care-
fully analysed the proliferation rate of α-SMA-positive ﬁbroblasts
in archived tissue from a previously published preclinical trial.28
Co-immunoﬂuorescence staining revealed a proliferation rate of
2%–5% in α-SMA-positive cells in vehicle-treated KPC tumours,
and this rate did not change on gemcitabine treatment (ﬁgure 6A,
B). Furthermore, co-immunohistochemistry for cleaved caspase-3
and α-SMA revealed a very low number of double positive cells
indicating that CAFs are intrinsically resistant to gemcitabine in
vivo (ﬁgure 6C, D). We speculate that the discrepancy between in
vitro and in vivo chemosensitivity of CAFs is most likely due to
the differences in proliferation rates, but that other factors such
as prosurvival cues mediated between tumour cells and the micro-
environment may also play a role.
Following our hypothesis that ﬁbroblast scavenging is more
prevalent in lesions with high ﬁbroblast density, we aimed to
test the response of gemcitabine on primary tumours and liver
metastases in a historical cohort of KPC mice that had been
treated with either vehicle (n=8) or gemcitabine (n=8) for
9 days.28 To this end, we quantiﬁed all liver metastases in 10
serial sections (each 40 mm apart) to assess the effects of gemci-
tabine on the overall frequency of metastases. Notably, we
found a reduction of liver metastases by 50% following gemcita-
bine treatment, and this effect was most pronounced (68%
reduction) when only small liver metastases were analysed
(ﬁgure 6E–G). In contrast, corresponding primary KPC tumours
were only reduced in volume by 14% on treatment conﬁrming
multiple previous reports from various groups that gemcitabine
only mildly affects primary KPC tumours (ﬁgure 6H). When
comparing the apoptotic rate of primary KPC tumours and cor-
responding liver metastases, we detected higher, albeit not sig-
niﬁcantly elevated levels of apoptotic tumour cells in liver
metastases compared with primary tumours (see online
supplementary ﬁgure S9A, B).
DISCUSSION
Despite the fact that gemcitabine is a highly active drug in vitro,
monotherapy fails to show meaningful antitumour effects in
patients with PDAC and genetically engineered mice. Apart
from biochemical signalling loops within the tumour micro-
environment,33–38 impaired drug delivery caused by stroma-rich
and hypovascular tumours has been debated as one of the main
reasons for the failure of anticancer agents in PDAC. However,
antistromal approaches have failed in patients, and the increase
in drug delivery may not necessarily imply that the anticancer
compound is metabolically available and active against tumour
cells. Indeed, a previous preclinical study conducted in our
laboratory showed that systemic and intratumoural elevation of
gemcitabine by cotreatment with a pharmacological inhibitor of
gemcitabine inactivation (tetrahydrouridine) did not affect
tumour volume or apoptotic rate in primary tumours.28
These considerations prompted us to reassess drug delivery in
pancreatic cancer with a particular focus on the predominant
cell types, that is, stromal cells and tumour cells. Our data show
that gemcitabine accumulated in ﬁbroblast-rich KPC tumours
more effectively than in liver metastases displaying less desmo-
plasia and CAFs. This result was surprising as we had expected
to see similar or higher levels of drug in liver metastases, which
are surrounded by the well-perfused liver. In vitro, ﬁbroblasts
revealed a drug scavenging effect by metabolising gemcitabine
thus entrapping signiﬁcant amounts of dFdCTP that are not
available for tumour cells anymore. Assuming that gemcitabine
scavenging is more pronounced in bulk KPC tumours with
strong desmoplasia, we investigated the effects of gemcitabine
treatment on the frequency of liver metastases. On gemcitabine
treatment, the number of all metastases was reduced by more
than half, and this effect was particularly pronounced in small,
only microscopically visible metastases. The effective killing of
metastases and circulating tumour cells on gemcitabine has been
recently proposed in a preclinical study. Metastatic lesions of
all size were shown to have signiﬁcantly higher apoptotic rates
than primary tumours, and the metastatic burden was robustly
reduced following long-term treatment with gemcitabine and
nab-paclitaxel.39 The authors suggested that epithelial-to-
mesenchymal transition in metastatic lesions may have pro-
moted chemosensitivity towards nab-paclitaxel and gemcitabine.
Thus, these observations together with our data may explain
why gemcitabine affords a survival beneﬁt in resected patients
by targeting small metastases prior to clinical detection.
The reduced content of α-SMA ﬁbroblasts in murine and
human liver metastases compared with matched primary
tumours is intriguing. Although the small set of matched human
samples appear to conﬁrm our murine data, conﬁrmation from
a larger set of human samples is required. Our observation is in
contrast to previously published data that describe comparable
stromal components in liver metastases and primary tumours.40
However, matched samples were only available in seven cases,
and α-SMA staining was not performed for the matched
dataset.40 Interestingly, a recent publication from the Stanger
laboratory investigated the dynamic changes of the tumour
stroma during progression from single metastatic cells to nano-
metastases, micrometastases, millimetastases and macrometas-
tases in the KPCY mouse model. In line with our data, the
authors reported reduced SPARC, collagen and α-SMA immu-
noreactivity in nanometastases, micrometastases and millimetas-
tases.39 Although α-SMA staining was not performed for
matched human metastases and primary tumours, the authors
found that macrometastases became increasingly more desmo-
plastic and eventually recapitulated the primary tumour.39 In
our study, we randomly used liver metastases for LC-MS/MS
analysis but did not categorise lesions in several subgroups. Due
to the small size of mouse liver metastases, we were also not
able to simultaneously assess and correlate the stromal content
and gemcitabine concentration in identical metastatic lesions.
Mechanistically, we found a number of gemcitabine metabolis-
ing enzymes with low expression in stromal cells that would
explain the increased amount of gemcitabine and its activated
metabolite. The two main gemcitabine inactivating enzymes are
Cda and Dctd, and both act at different nodes during gemcitabine
metabolism. Whereas Cda quickly inactivates gemcitabine to
dFdU, Dctd metabolises dFdCMP to dFdUMP preventing further
activation of dFdCMP to dFdCTP. To the best of our knowledge,
differential expression of Nt5cAs in pancreatic cancer cells and
ﬁbroblasts has not been reported before. Since Nt5cAs catalyse the
hydrolysis from dFdCMP to gemcitabine, it seems like the most
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suitable target for reprogramming the tumour stroma may be by
decreasing dFdCTP concentrations in CAFs.
Furthermore, our results may also provide an explanation
why the extent of desmoplasia was often reported to be nega-
tively correlated with patient survival.33 40 41 As most of the
previous prognostic datasets were derived from patients treated
with gemcitabine, the high number of activated CAFs may have
acted as a biomarker for poor drug response due to ﬁbroblast
drug scavenging.
Although ﬁbroblast-depletion approaches may appear attract-
ive for patients with PDAC to increase the intratumoural avail-
ability of gemcitabine for cancer cells, several studies recently
reported that pharmacological and genetic depletion of activated
ﬁbroblasts results in accelerated pancreatic tumour growth,
increased invasiveness, stemness and immune-modulation.42–45
Therefore, stromal and immunological reprogramming rather
than CAF ablation is currently pursued as one potentially success-
ful strategy to overcome therapy resistance.45–49 Our data further
support this strategy showing that the metabolic programme of
activated ﬁbroblasts may lead to intratumoural drug redistribu-
tion and shift towards stromal cells rather than tumour cells. This
drug scavenging effect of CAFs may be critical for therapeutic
efﬁcacy in pancreatic cancer, especially when several chemothera-
pies are combined. And indeed, we have recently shown that
treatment with nab-paclitaxel increases intratumoural gemcita-
bine levels by reducing the levels of Cda protein in cancer cells
through induction of reactive oxygen species-mediated degrad-
ation.18 This mechanism may partly explain the synergistic effect
of this combination treatment in patients with pancreatic cancer.5
In conclusion, multiple studies suggest that impaired drug
delivery is a major reason for the failure of therapeutic agents in
pancreatic cancer. With our study, we add another layer of com-
plexity showing that ﬁbroblast drug scavenging increases intratu-
moural gemcitabine accumulation entrapping active gemcitabine
within stromal cells thus making it unavailable for tumour cells.
However, we cannot exclude the possibility that increasing drug
delivery by modulating vessel patency and density might still
have beneﬁcial therapeutic effects in PDAC. Our data provide
an alternative explanation for the failure of gemcitabine in
PDAC and challenge the paradigm of a biophysical stroma
barrier for gemcitabine delivery. Targeting the metabolic pro-
gramme in CAFs may thus be a promising strategy to enhance
the antiproliferative effects of gemcitabine in PDAC.
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